Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02321176
Other study ID # Sun2
Secondary ID
Status Recruiting
Phase N/A
First received June 7, 2014
Last updated December 16, 2014
Start date March 2014
Est. completion date April 2015

Study information

Verified date December 2014
Source Huazhong University of Science and Technology
Contact Wang Shuaishuai
Phone 15623422892
Email 949990624@qq.com
Is FDA regulated No
Health authority China: Ethics Committee
Study type Interventional

Clinical Trial Summary

There is blood-eye barrier in eyes,but some oral medicines can enter in the tissues of eyes.

The primary objective of the study is to study the Pharmacokinetics of Trans-resveratrol and Its three Metabolites in Human Eyes and Blood


Description:

This was a single-blind, randomised study investigating single oral dose of LONGEVINEX in two groups of about 20 Patients with rhegmatogenous retinal detachment retinal detachment(males and females).The subjects received 100mg LONGEVINEX everyday,a total of three days before surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date April 2015
Est. primary completion date April 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

1. Patients with rhegmatogenous retinal detachment.

2. Male and female patients 18-60 years of age.

3. nonsmokers or who smoke<10 cigarettes/day.

4. BMI ranging from 19 to 30 kg/m^2 were eligible for the study.

5. Patients were considered to be healthy on the basis of electrocardiogram (ECG), and clinical laboratory safety tests (haematology, plasma biochemistry, urinalysis and hepatitis B, hepatitis C and HIV serology) performed at screening.

6. Women use measures to avoid conception during the study period (e.g. oral contraceptives, intrauterine devices [IUDs], and condoms).

7. Avoid ingesting grapefruit, grapefruit juice or other grapefruit juice containing products, and any herbal-based nutrient supplement or prescribed medications( grapefruit, cranberry, blueberry products, peanuts and peanut butter, grape and grape products, and red wine ) during the same period of time.

8. patients should abstain from alcohol-containing beverages at least two days prior to and during the study.

Exclusion Criteria:

1. Uncontrolled Blood pressure exceeding diastolic pressure of 100 mm Hg (sitting) during the screening period and uncontrolled diabetes mellitus

2. Participation in another simultaneous medical investigation or trial

3. Renal failure requiring dialysis or renal transplant or liver dysfunction History of other disease,or other findings giving reasonable suspicion of a disease or condition that contraindicates the use an investigational drug, might affect interpretation of the results of the study, or render the subject at high risk from treatment complications.5.IOP over 30 mmHg.

4. Any previous retinal laser photocoagulation to the study eye in treatment naive. Any previous intravitreal injection in study eye (triamcinolone or other) in treatment naive.

5. Any previous vitrectomy in study eye (posterior or anterior associated with vitreous loss in cataract surgery). Intracapsular cataract extraction (posterior capsule needs to be present).

6. Aphakia or absence of the posterior capsule in the study eye, Structural damage to the center of the macula in the study eye preexisting to CRVO likely to preclude improvement in visual acuity following the resolution of macular edema, including atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s).

Study Design

Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)


Related Conditions & MeSH terms


Intervention

Drug:
trans-resveratrol
patients received 100mg Longevinex everyday,total of three days 1 capsule daily for one day containing 100 mg of trans resveratrol active ingredient

Locations

Country Name City State
China Tongji Medical College of HUST Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Huazhong University of Science and Technology

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tmax 1 capsule containing 100 mg of trans resveratrol active ingredient daily for three days.Than detect the concentrations of the tissues from the eyes of the surgery. up to three days Yes
See also
  Status Clinical Trial Phase
Recruiting NCT02500862 - Characterization of Potential Biomarkers of Eye Disease and Vision
Completed NCT02003547 - A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy Subjects Phase 1
Completed NCT01693315 - Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma Phase 2
Recruiting NCT02321189 - The Effect of Resveratrol Based Nutritional Supplement on Choroidal Thickness N/A
Completed NCT00073099 - Digital Photography to Evaluate Dry Eye N/A
Completed NCT00678860 - Validation of Computerized Vision-Targeted Quality-of-Life Questionnaires N/A
Completed NCT00957190 - The DIOXXACT Trial(Diurnal IOP and OBF Xalatan vs Xalatan And Cosopt Trial) Phase 4
Active, not recruiting NCT00386906 - Sentinel Lymph Node (SLN) Biopsy for Conjunctival/Eyelid Melanoma Phase 1
Completed NCT00001737 - Cyclosporin Implant to Treat Uveitis Phase 1
Completed NCT04912622 - RPE Characterisation With Transscleral Optical Phase Imaging in Retinal Disorders N/A
Completed NCT00591110 - Project inCharge: Increasing the Rate of Comprehensive Eye Care Utilization by Older African Americans Through Community-Based Eye Health Education Program N/A
Unknown status NCT00649766 - Tailored Messages to Increase Eye Examination Behavior N/A
Completed NCT02851251 - Multicenter Neonatal Eye Disease Screening in China
Active, not recruiting NCT01648452 - CNTF Implants for CNGB3 Achromatopsia Phase 1/Phase 2
Enrolling by invitation NCT01396967 - Trying a New Device for Performing Capsulorhexis in Cataract Surgery Surgery Phase 1
Completed NCT00270647 - Physicians' Health Study II N/A
Completed NCT00001224 - Analysis of Eye Tissue N/A
Completed NCT00473278 - Analysis of Human Tear Proteins in Children N/A
Terminated NCT00453258 - Pilot Study of Human Tear Proteins N/A
Recruiting NCT02821767 - Natural History, Pathogenesis, and Outcome of Ocular Disorders